share_log

MicroPort Scientific (HKG:853) Adds HK$550m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 88%

MicroPort Scientific (HKG:853) Adds HK$550m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 88%

微创科技(HKG: 853)在过去7天内市值增加了5.5亿港元,尽管三年前的投资者仍下跌了88%
Simply Wall St ·  01/29 17:27

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of MicroPort Scientific Corporation (HKG:853) investors who have held the stock for three years as it declined a whopping 88%. That might cause some serious doubts about the merits of the initial decision to buy the stock, to put it mildly. And over the last year the share price fell 75%, so we doubt many shareholders are delighted. Furthermore, it's down 49% in about a quarter. That's not much fun for holders. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

正如每个投资者所知道的那样,并非每一次波动都能达到最佳水平。但是,如果你不止一次地面临巨额损失,你就会遇到问题。因此,暂时考虑一下微创科学公司(HKG: 853)投资者的不幸,他们持有该股三年,跌幅高达88%。客气地说,这可能会使人们严重怀疑最初购买该股票的决定的优点。在过去的一年中,股价下跌了75%,因此我们怀疑许多股东是否感到高兴。此外,它在大约一个季度内下降了49%。对于持有者来说,这没什么好玩的。在这种情况下,我们真的对股东有同感。这很好地提醒了多元化的重要性,无论如何,值得记住的是,生活中存在的不仅仅是金钱。

While the stock has risen 5.1% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

尽管该股在过去一周上涨了5.1%,但长期股东仍处于亏损状态,但让我们看看基本面能告诉我们什么。

View our latest analysis for MicroPort Scientific

查看我们对微创科技的最新分析

MicroPort Scientific wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

MicroPort Scientific在过去十二个月中没有盈利,我们不太可能看到其股价与每股收益(EPS)之间存在很强的相关性。可以说,收入是我们的下一个最佳选择。一般而言,没有利润的公司预计每年收入将增长,而且速度很快。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。

In the last three years, MicroPort Scientific saw its revenue grow by 10% per year, compound. That's a fairly respectable growth rate. So it's hard to believe the share price decline of 24% per year is due to the revenue. More likely, the market was spooked by the cost of that revenue. This is exactly why investors need to diversify - even when a loss making company grows revenue, it can fail to deliver for shareholders.

在过去的三年中,MicroPort Scientific的收入每年增长10%,复合增长。这是一个相当可观的增长率。因此,很难相信股价每年下跌24%是由于收入造成的。更有可能的是,这笔收入的成本吓坏了市场。这正是投资者需要分散投资的原因——即使亏损公司增加了收入,也可能无法为股东带来收益。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。

earnings-and-revenue-growth
SEHK:853 Earnings and Revenue Growth January 29th 2024
SEHK: 853 2024年1月29日收益和收入增长

This free interactive report on MicroPort Scientific's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想进一步调查该股,这份关于MicroPort Scientific资产负债表实力的免费互动报告是一个很好的起点。

A Different Perspective

不同的视角

We regret to report that MicroPort Scientific shareholders are down 75% for the year. Unfortunately, that's worse than the broader market decline of 20%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for MicroPort Scientific that you should be aware of.

我们遗憾地报告,微创科学的股东今年下跌了75%。不幸的是,这比整个市场20%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。遗憾的是,去年的业绩结束了糟糕的表现,股东在五年内每年面临3%的总亏损。我们意识到罗斯柴尔德男爵曾说过,投资者应该 “在街头流血时买入”,但我们警告说,投资者应首先确保他们购买的是高质量的企业。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们已经为 MicroPort Scientific 确定了一个你应该注意的警告信号。

Of course MicroPort Scientific may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

当然,微创科技可能不是最值得购买的股票。因此,您可能希望看到这批免费的成长股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发